CTA works with some of the largest global pharmaceutical companies and CROs to support their drug developments programs in Australia. We aim to be the partner of choice for clinical trials by focusing on quality and timeliness at a reasonable cost. CTA has been involved in numerous national and international Phase I-III trials with many different molecules from small chemical agents to biological agent that include antibodies and therapeutic vaccines.

Since our inception, CTA has facilitated over 1000 clinical trials and the recruitment of over 10,000 patients.

We operate with the highest ethical standards and believe our experience, expertise and cost effectiveness is reflected in our repeat business and the profiles of the clients we attract.

Collaboration is the key to achieving CTA’s goals. Through our engagement with industry and network of Members, CTA is able to provide the ideal environment to support and drive drug development programs within Australia.

A specialised Phase I trial group is available within CTA to provide advice on trial design, translational drug development and protocol development.

CTA is capable of facilitating Phase I trials across all tumour types, in tumour specific or molecular target specific studies.

Australia is recognised as a hub for early phase trials and many international biotech companies have successfully conducted early phase trials in Australia

NOTE FOR NAT **some of this info is repeated on “Early engagement page – where is it better located?****